Moderna (MRNA) excited analysts, though not as much investors, with its announcement this week that it planned to file for approval of its mRNA vaccine designed to protect older adults against respiratory syncytial virus (RSV) after it demonstrated success in a Phase III trial.
After…
Source: www.genengnews.com – Read more
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
